When it comes to prostate cancer, you often hear terms like biopsy, MRI, or PSA test. But one word is becoming increasingly common: biomarkers.

Found in blood, tissue, or urine, these biological indicators not only help better understand the progression of cancer but also guide personalized treatment decisions.

In this article, we will cover:

• What a biomarker is and its purpose;
• The main biomarkers used in prostate cancer and how they influence treatment decisions;
• Emerging biomarkers currently in development.

Medical review by uro-oncologist Dr. Paul Toren, December 2025

What is a biomarker?

A biomarker is a measurable substance in the body, such as a protein, gene, or cell fragment, that provides information about a biological process or disease.

In prostate cancer, biomarkers help healthcare professionals to:

• Detect the presence of cancer;
• Predict its progression;
• Choose the most appropriate treatment;
• Evaluate the response to therapy.

Key biomarkers in prostate cancer

PSA (Prostate-Specific Antigen)

This is the most commonly used biomarker. PSA levels are regularly monitored to assess treatment response or detect recurrence. However, PSA alone does not provide a complete picture: a high PSA does not always mean cancer, and a low PSA does not rule out aggressive disease.

Genetic and molecular biomarkers

Recent tests can examine the genes present in cancer cells. By studying their activity, doctors can estimate how the cancer is likely to behave—whether slow-growing or aggressive.

These tests can:

• Avoid unnecessary aggressive treatments, opting for active surveillance if the cancer progresses slowly;
• Guide earlier or more intensive treatment if the risk is higher.

They provide a more precise and personalized follow-up, helping to avoid both overtreatment and undertreatment.

Emerging biomarkers

Currently under study or recently introduced in clinical practice, these biomarkers pave the way for more precise, personalized medicine. They can be detected in blood, urine, tumor cells, or as circulating tumor DNA fragments—known as liquid biopsy.

These new tools, although not yet widely used, could allow:

• Real-time monitoring of cancer progression without invasive biopsies;
• Early detection of recurrence, sometimes before PSA levels rise;
• Assessment of resistance or sensitivity to certain treatments, such as hormone therapy, chemotherapy, or targeted therapies—for example, some emerging biomarkers may indicate whether a patient will respond better to PARP inhibitors or therapies targeting specific genetic mutations;
• Identification of specific genetic abnormalities that may provide access to new treatments, including clinical trials.

These advanced analyses offer a finer understanding of the disease, enable treatment adjustments in real time, and could one day complement or replace traditional tests like PSA.

Biomarkers in brief

• Biomarkers help better understand, monitor, and treat prostate cancer.
• PSA remains useful, but additional biomarkers provide a more precise view of cancer behavior.
• Some genetic tests allow treatments to be tailored to the tumor’s biological profile.
• They contribute to more personalized, effective, and patient-centered care.

Next steps

• Discuss with your healthcare team which tests are relevant to your situation;
• Ask if genetic or molecular tests could be useful;
• Evaluate whether active surveillance, targeted therapy, or participation in a clinical trial is appropriate;
• Stay informed of new developments, as this field is rapidly evolving.

At PROCURE, we believe that better understanding leads to better living with the disease. Our professionals are here to support you and answer your questions, seven days a week. Contact us at 1-855-899-2873 or visit our website procure.ca